These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 34552580)

  • 1. The Immune Landscape of Chinese Head and Neck Adenoid Cystic Carcinoma and Clinical Implication.
    Dou S; Li R; He N; Zhang M; Jiang W; Ye L; Yang Y; Zhao G; Yang Y; Li J; Chen D; Zhu G
    Front Immunol; 2021; 12():618367. PubMed ID: 34552580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands.
    Mosconi C; de Arruda JAA; de Farias ACR; Oliveira GAQ; de Paula HM; Fonseca FP; Mesquita RA; Silva TA; Mendonça EF; Batista AC
    Oral Oncol; 2019 Jan; 88():95-101. PubMed ID: 30616805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Profiling and the Impact of Treatment on Outcomes in Adenoid Cystic Carcinoma Type I and II.
    Hanna GJ; Grover P; Elliott A; McGrath J; Xiu J; Sukari A; Johnson JM; Wise-Draper T
    Clin Cancer Res; 2024 May; 30(10):2225-2232. PubMed ID: 38416410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of immune response biomarkers (PD‑L1, p16, CD3+ and CD8+ TILs) in recurrent head and neck squamous cell carcinoma within previously irradiated areas.
    Pflumio C; Thomas J; Salleron J; Faivre JC; Borel C; Dolivet G; Sastre-Garau X; Geoffrois L
    Oncol Rep; 2021 Mar; 45(3):1273-1283. PubMed ID: 33432367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
    Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
    J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes.
    Sridharan V; Gjini E; Liao X; Chau NG; Haddad RI; Severgnini M; Hammerman P; El-Naggar A; Freeman GJ; Hodi FS; Rodig SJ; Dranoff G; Schoenfeld JD
    Cancer Immunol Res; 2016 Aug; 4(8):679-87. PubMed ID: 27312343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Efficacy of Immunotherapy and Clinical Utility of Comprehensive Genomic Profiling in Adenoid Cystic Carcinoma of Head and Neck.
    Naito T; Noji R; Kugimoto T; Kuroshima T; Tomioka H; Fujiwara S; Suenaga M; Harada H; Kano Y
    Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138214
    [No Abstract]   [Full Text] [Related]  

  • 9. Programmed Cell Death Ligand-1 (PDL-1) Correlates With Tumor Infiltration by Immune Cells and Represents a Promising Target for Immunotherapy in Endometrial Cancer.
    Hecking T; Thiesler T; Halbe J; Otten L; Recker F; Gevensleben H; Müller T; Schiller C; Egger EK; Fimmers R; Stope MB; Kristiansen G; Mustea A
    Anticancer Res; 2022 Mar; 42(3):1367-1376. PubMed ID: 35220229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
    Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
    Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An increase of CD8
    So YK; Byeon SJ; Ku BM; Ko YH; Ahn MJ; Son YI; Chung MK
    Sci Rep; 2020 Nov; 10(1):20059. PubMed ID: 33208791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution pattern of tumor infiltrating lymphocytes and tumor microenvironment composition as prognostic indicators in anorectal malignant melanoma.
    Kim SW; Kim YI; Mustafa B; Kim MJ; Jeong G; Ahn SM; Lim SB; Yu CS; Kim JC; Hong SM; Park IJ
    Mod Pathol; 2021 Jan; 34(1):141-160. PubMed ID: 32709987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma.
    Lim SM; Kang SS; Kim DK; Lee SH; Synn CB; Baek S; Yang SM; Han YJ; Kim MH; Han H; Na K; Kim YT; Yun MR; Kim JH; Byeon Y; Kim YS; Lee JB; Hong MH; Curtin JC; Patel B; Bergiers I; Pyo KH; Cho BC
    Cancer Res Commun; 2024 Jul; 4(7):1748-1764. PubMed ID: 38916448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors.
    Deng B; Park JH; Ren L; Yew PY; Kiyotani K; Antic T; O'Connor K; O'Donnell PH; Nakamura Y
    Cancer Rep (Hoboken); 2018 Jun; 1(1):e1002. PubMed ID: 32729250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment Of Tumour Infiltrating Lymphocytes And Pd-l1 Expression In Adenoid Cystic Carcinoma Of The Salivary Gland.
    Chen W; Fung AS; McIntyre JB; Simpson R; Afzal AR; Hao D; Lau H
    Clin Invest Med; 2021 Mar; 44(1):E38-41. PubMed ID: 33743575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    Lyu X; Wang P; Qiao Q; Jiang Y
    BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary.
    Sue-A-Quan R; Patel PG; Shakfa N; Nyi MN; Afriyie-Asante A; Kang EY; Köbel M; Koti M
    Gynecol Oncol; 2021 Aug; 162(2):421-430. PubMed ID: 34088514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
    Okamoto I; Sato H; Tsukahara K
    Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
    Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
    Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment-induced changes of lymphocyte subsets in patients with adenoid cystic carcinoma of the head and neck.
    Jeske SS; Weissinger SE; Veit JA; Brunner C; Huber U; Theodoraki MN; Hoffmann TK; Schuler PJ; Doescher J
    Eur Arch Otorhinolaryngol; 2019 May; 276(5):1465-1473. PubMed ID: 30815724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.